Vertaling van "legal advice and information " (Nederlands → Frans) :

Transposing European regulations into national law ●● Coordination of international relations ●● Legal advice and information ●● Disputes
Transposing European regulations into national law ●● Coordination of international relations ●● Legal advice and information ●● Disputes

Odds ratio of NRT versus control: 1.67 Odds ratio of bupropion versus control: 2.1 Odds ratio of NRT+bupropion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+bupropion: 0.0805 treated quit rate for brief advice+bupropion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+bupropion: 0.1892 treated quit rate for counselling+bupropion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.
Odds ratio of NRT versus control: 1.67 Odds ratio of Buproprion versus control: 2.1 Odds ratio of NRT+Buproprion versus control: 2.65 From these Odds Ratios and information on the control 12-month quit rate in the comparator intervention (0.04 for brief advice and 0.10 for counselling), the 12-month quit rate of treatment is calculated: treated quit rate for brief advice+NRT: 0.0650 treated quit rate for brief advice+Buproprion: 0.0805 treated quit rate for brief advice+Buproprion+NRT: 0.0994 treated quit rate for counselling+NRT: 0.1565 treated quit rate for counselling+Buproprion: 0.1892 treated quit rate for counselling+Buproprion+NRT: 0.2275 spontaneous cessation rate: 0.01. lifetime relapse rate: 40% (range 30-50%). number of LYG per quitter: 2 (range 1-3). number of QALYs gained per quitter: 2.7 (range 1.35-4.05) not reported The table gives an overview of the assumptions with respect to costs and effects (quit rates) in the average scenario.

In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information
In close cooperation with Mdeon, the FAMHP has mainly focused on the provision of information to the relevant parties, i.e. companies and healthcare professionals, during this first operational year A “contact point” collects and processes information about actions that may constitute an infringement of the legal requirements about advertising. In terms of advertising for healthcare professionals, attention is particularly being focused at present on the conformity of the legally required information

This case-manager’s tasks consist of 1) following-up on the assessment and the counselling of suicidal patients at the hospital, 2) informing the GP, 3) co-ordinating the follow-up care provided once the patient has left hospital, 4) giving advice to the GPs on suicide prevention.
Les tâches de ce case-manager comprennent 1) le suivi de l’assessment et l’encadrement des patients suicidaires à l’hôpital; 2) l’information du médecin généraliste; 3) la coordination du suivi post-hospitalier; 4) des avis aux médecins généralistes sur la prévention du suicide.

The Symbio Mutual Insurance Company keeps you informed and is available for personalized advice.
La Mutualité Symbio vous informe et se tient à votre disposition pour tout conseil personnalisé.

In order to regulate the quality and relevance of messages to the public, a prior licence is required for radio and TV information campaigns about human health and illness which refer directly or indirectly to medicines. This licence is normally issued by the Minister responsible following advice from the Commission for the supervision of advertising for medicines for human use.
In order to regulate the quality and relevance of messages to the public, a prior licence is required for radio and TV information campaigns about human health and illness which refer directly or indirectly to medicines. This licence is normally issued by the Minister responsible following advice from the Commission for the supervision of advertising for medicines for human use.

- Contact) ●● Providing information about the legal context and procedures ●● Providing information about medicines and
- Contact) ●● Providing information about the legal context and procedures ●● Providing information about medicines and

Support services 45 Budget & Management Control 45 Information & Communication Technology 49 Legal service 52 Translation service 53 Personnel & Organisation 53
Support services 45 Budget & Management Control 45 Information & Communication Technology 49 Legal service 52 Translation service 53 Personnel & Organisation 53

Among others, these include Budget & Management Control (B&Mc), Information & Communication Technology (ICT), the Legal service, Personnel & Organisation (P&O), the Translation service, Communication & Scientific support, International Relations, PMO (the support monitoring unit), Internal Audit & Quality and the Crisis unit (non-permanent).
Among others, these include Budget & Management Control (B&Mc), Information & Communication Technology (ICT), the Legal service, Personnel & Organisation (P&O), the Translation service, Communication & Scientific support, International Relations, PMO (the support monitoring unit), Internal Audit & Quality and the Crisis unit (non-permanent).

The BUM department is legally required to provide support with putting online the list of medicines authorised in Belgium for new medicine MA and of the official information (Summary of Product Characteristics for healthcare professionals and leaflet for the general public).
The BUM department is legally required to provide support with putting online the list of medicines authorised in Belgium for new medicine MA and of the official information (Summary of Product Characteristics for healthcare professionals and leaflet for the general public).